Personlig profil
Expertise
- Design of clinical trials according to Good Clinical Practice
- Work in lab: Cell culturing, flowcytometry
- Especially knowledge in malignant melanoma
Primære forskningsområder
Oncology: In more detail cancer immunotherapy: The use of a persons immune system to fight cancer; i.e. with monoclonal antibodies, cancer vaccines and T cell therapy. My main research area is to test safety, toxicity an clinical efficacy of peptide vaccines consisting of PD-L1 and IDO peptides in combination with the standard treatment Nivolumab (PD-1 blocking antibody) (first in patient with malignant melanoma, and hopefully expand to other cancer types).
Aktuel forskning
Clinical trial with the title: "Combination therapy with Nivolumab and PD-L1/IDO peptide vaccine to patients with metastatic melanoma. Inclusion of the first patient in March 2017.
Mulige interessekonflikter
No conflicts of interest
Fingeraftryk
- 1 Lignende profiler
Samarbejde og topforskningsområder i de sidste fem år
Publikation
-
Safety and feasibility of blood-derived multiple antigen-specific endogenously derived T cells (MASE-T) for metastatic melanoma
Monberg, T. J., Tvingsholm, S. A., Svensson-Frej, M., Vestergaard, C., Ormhøj, M., Kjeldsen, J. W., Borch, T. H., Holmstroem, R. B., Jayashankar, N., Granhøj, J. S., Cordt, A. R., Larsen, S. K., Met, Ö., Hadrup, S. R. & Svane, I. M., mar. 2026, I: Immuno-oncology technology. 29, s. 101581 101581.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
-
Five-year clinical outcome and immune biomarkers of durable response from the MM1636 trial on IDO/PD-L1 vaccination and PD-1 blockade in first line metastatic melanoma
Pedersen, S., Byrdal, M., Martinenaite, E., Lorentzen, C. L., Kjeldsen, J. W., Thorsen, S. U., Kverneland, A., Zocca, M.-B., Andersen, M. H. & Svane, I. M., 14 dec. 2025, I: Nature Communications. 17, 1, s. 806 806.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
-
The antitumor activity of TGFβ-specific T cells is dependent on IL-6 signaling
Perez-Penco, M., Byrdal, M., Lara de la Torre, L., Ballester, M., Khan, S., Siersbæk, M., Lecoq, I., Madsen, C. O., Kjeldsen, J. W., Svane, I. M., Hansen, M., Donia, M., Johansen, J. S., Olsen, L. R., Grøntved, L., Chen, I. M., Arnes, L., Holmström, M. O. & Andersen, M. H., jan. 2025, I: Cellular & Molecular Immunology. 22, 1, s. 111-126 16 s., 104659.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
12 Citationer (Scopus) -
First in man study: Bcl-Xl_42-CAF®09b vaccines in patients with locally advanced prostate cancer
Mørk, S. K., Kongsted, P., Westergaard, M. C. W., Albieri, B., Granhøj, J. S., Donia, M., Martinenaite, E., Holmström, M. O., Madsen, K., Kverneland, A. H., Kjeldsen, J. W., Holmstroem, R. B., Lorentzen, C. L., Nørgaard, N., Andreasen, L. V., Wood, G. K., Christensen, D., Klausen, M. S., Hadrup, S. R. & Thor Straten, P. & 2 flere, , 14 mar. 2023, I: Frontiers in Immunology. 14, 15 s., 1122977.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
9 Citationer (Scopus) -
Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
Lorentzen, C. L., Kjeldsen, J. W., Ehrnrooth, E., Andersen, M. H. & Marie Svane, I., maj 2023, I: Journal for ImmunoTherapy of Cancer. 11, 5, e006755.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
30 Citationer (Scopus)